



Cleoderm™

Compatibility Table



Table 1. List of compatible APIs/DCIs

API / DCI	Range of tested concentration (bracketed study)	Results
Adapalene	0.1% to 0.3%	0.1% ● / 0.3% ●
Alpha arbutin	0.5% to 2.0%	● *
Alpha bisabolol	0.5% to 2.0%	● *
Azelaic acid	10.0% to 25.0%	● *
Benzoyl peroxide	2.5% to 10.0%	●
Brimonidine tartrate	0.2% to 0.5%	● *
Clindamycin	1.0% to 3.0%	● *
Cyproterone acetate	0.5% to 2.0%	●
Dapsone	5.0% to 10.0%	●
Ellagic acid	0.25% to 1.0%	● *
Enoxolone	0.5% to 2.5%	0.5% ● / 2.5% ●
Erythromycin	1.0% to 4.0%	● *
Estriol	0.1% to 1.0%	●
Glycolic acid	2.0% to 10.0%	● *
Hydroquinone	2.0% to 10.0%	2.0% ● / 10.0% ●
Kojic acid	1.0% to 4.0%	● *
Mandelic acid	2.0% to 10.0%	● *
Metronidazole	0.75% to 5.0%	●
Niacinamide	1.0% to 5.0%	●
Progesterone	0.5% to 2.0%	●
Spironolactone	0.5% to 2.0%	●
Tranexamic acid	1.0% to 5.0%	●
Tretinoin	0.01% to 0.1%	●
Vitamin C	5.0% to 20.0%	●
Zinc pyrithione	1.0% to 2.0%	● *

Compatible combination for

● 15 days
 ● 30 days
 ● 35 days
 ● 60 days
 ● 90 days
 ● 120 days
 ● 150 days
 ● 180 days

* Estimated beyond-use date (compatibility study in progress). In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days.





Table 2. List of compatible API/DCI associations.

API / DCI Associations	Range of tested concentration (bracketed study)	Results
Adapalene + benzoyl peroxide	0.1% + 1.0% to 0.3% + 10.0%	○*
Azelaic acid + Niacinamide	1.0% + 1.0% to 25.0% + 4.0%	○*
Clindamycin + Niacinamide + Benzoyl peroxide	1.0% + 1.0% + 1.0% to 3.0% + 10.0% + 4.0%	○*
Erythromycin + Tretinoin	1.0% + 0.01% to 5.0% + 0.05%	○*
Metronidazole + Niacinamide	0.75% + 1.0% to 2.0% + 5.0%	○*
Tretinoin + Niacinamide	0.0125% + 4.0% to 0.035% + 6.0%	○*
Tretinoin + Tranexamic acid + Hydroquinone + Hydrocortisone	0.0125% + 2.5% + 4.0% + 1.0% to 0.035% + 2.5% + 4.0% + 1.0%	○*

Compatible combination for

- 15 days
 ● 30 days
 ● 35 days
 ● 60 days
 ● 90 days
 ● 120 days
 ● 150 days
 ● 180 days

* Estimated beyond-use date (compatibility study in progress). In the absence of stability information, the USP <795> can be used as a guideline, which advises a BUD of no more than 35 days.




COMPOUNDING WITH CLEODERM™

Cleoderm™ is an easy to compound-with vehicle, compatible with a wide range of active pharmaceutical ingredients (APIs) and dermatological ingredients (DCIs), and different associations. Up to 10% of solvents or levigants can be added to assist the compounding without affecting the final stability of the formulation.

The final product can be compounded by combining the APIs/DCIs, solvents, and **Cleoderm™** in an appropriate size FagronLab™ mixing jar, mixing for 3 to 4 minutes in the respective FagronLab™ EMP mixing machine, at a medium rotation speed. Process through an ointment mill if needed.

The beyond-use dates were determined using HPLC stability-indicating methods. Additional information is available upon request. The Estimated beyond-use date is a physical stability estimate based on data from published references, medical and scientific literature, observed organoleptic stability, formulator practical experience, and current USP guidelines. Please refer to USP Chapter <795> for additional information regarding appropriate Beyond-Use determination.



DISCLAIMER

This document contains examples of some commonly prescribed formulations across a diverse array of specialties, and they are not meant to encourage the use of any formula contained within. The customer is responsible for and, by its receipt of the Example Formula, agrees it will take any and all steps necessary to independently verify any formulation, concentrations, and raw amounts of components provided in this Example Formula, including any formulation that is the same or similar to the Example Formula, that is used in Customer's business to ensure the accuracy of all product components and component concentrations, as well as the compatibility and stability of all formulation components. Fagron, its owners, officers, agents, affiliates, and employees make no representation or warranty whatsoever with respect to these Example Formulas. Customer understands and agrees that Fagron, its owners, officers, agents, affiliates, and employees shall not be responsible for any claims, actions, liabilities, losses, expenses, damages, judgment, or costs arising directly or indirectly or related in any way to any actual or alleged injury to any person (including death) resulting from or claimed to result wholly or in part from any formulation that is the same or similar to any Example Formulas.

Together
we create the future
of personalizing medicine.



Fagron BV
Fascinatio Boulevard 350
3065 WB Rotterdam
The Netherlands

T +31 88 33 11 288
F +31 88 33 11 210
www.fagron.com

 **Fagron**
personalizing
medicine